Our Role in Society

The long journey of pharmaceuticals and medical technologies—from research and development to production and delivery to patients—involves numerous companies and complex systems. Established in 1955 as Japan's first pharmaceutical research organization, CRECON Research & Consulting has supported the advancement of the healthcare society and pharmaceutical industry for over 70 years, serving as a bridge between pharmaceutical wholesalers and manufacturers and medical institutions.

At CRECON Research & Consulting, using our proprietary network cultivated through years of research, reliable databases, and advanced software, we visualize the market landscape and provide objective evidence and perspectives to solve increasingly complex distribution challenges. Serving as the group’s core, we provide the strategic insights necessary to demonstrate and elevate the value of pharmaceutical distribution as a social infrastructure, thereby supporting a sustainable healthcare society and pharmaceutical industry.

The seamless delivery of pharmaceuticals and medical services to those in need is underpinned by advanced information networks. CRECON Group utilizes Japan's largest pharmaceutical database to accurately identify “when, where, and how much is required,” and thereby supporting stable supply and smooth distribution. This, so to speak, serves as a vital information infrastructure within the social safety net, ensuring uninterrupted medical care even during disasters or unforeseen circumstances.

MEDICODE, a joint venture with pharmaceutical wholesalers, enhances safety and efficiency across the entire medical supply chain by accurately maintaining and providing master data on pharmaceuticals and medical institutions, managing industry standard codes, and developing online transaction systems. Similarly, Encise, a joint venture with pharmaceutical wholesalers nationwide, analyzes vast amounts of distribution data daily to provide highly accurate demand forecasts. This contributes to the stable supply of pharmaceuticals and supports the establishment of information systems for the proper use of medicine. These efforts aim to put patients at ease as a common sense and provide healthcare professionals with a safer environment.

When new pharmaceuticals and medical technologies are developed, it is also indispensable to fairly evaluate the value that they bring to society, including from an economic perspective. CRECON Medical Assessment utilizes specialized techniques in pharmacoeconomics and Healthcare Technology Assessment (HTA) to scientifically evaluate the “true value” of pharmaceuticals and medical technologies. In doing so, we contribute to a sustainable society where high-quality healthcare is accessible to all.

Furthermore, addressing evolving healthcare needs is another crucial theme. At its core, Crecon Genomics leverages genome (genetic information) analysis technologies to advance research into disease risks and the development of innovative, highly accessible diagnostic technologies. Optimizing diagnosis and treatment based on genomic information and the optimal allocation of limited healthcare resources are two essential components for the future of medicine. Through the integration of these approaches, CRECON Group aims to deliver the best possible healthcare for both patients and society.

We believe that healthcare is ultimately driven by people. CRECON Group focuses on development of employees who will carry forward our long-standing medical expertise and commitment to continuously embracing new technologies to the next generation. Our group companies remain committed to meeting the ever-evolving needs of the healthcare field as well as shaping the future through dedicated pursuit of specialized expertise. Guided by our principles of trust, gratitude, and contribution to our customers and the entire society, we will continue to support Japan's healthcare system and everyone’s well-being.